Drugs / A Lyophilized COVID-19 mRNA Vaccine
A Lyophilized COVID-19 mRNA Vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05366296 Comparator | Jul → Sep 2022 | COVID-19 | Wuhan Recogen Biotechnology Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-06-27 | Shenzhen Rhegen Biotechnology Co.,Ltd. | Regulatory 瑞吉生物冻干新型冠状病毒 Omicron 株 mRNA 疫苗分别在新西兰和菲律宾获得临床批件 rhegen.com ↗
2022 年 6 月 27 日，深圳市瑞吉生物科技有限公司（以下简称"瑞吉生物"）宣布，其研发的冻干新型冠状病毒 Omicron 株 mRNA 疫苗 RH109 由下设合资公司（武汉瑞科吉生物科技有限公司） 分别在新西兰和菲律宾获得临床批件 。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-27 | Shenzhen Rhegen Biotechnology Co.,Ltd. | 瑞吉生物冻干新型冠状病毒 Omicron 株 mRNA 疫苗分别在新西兰和菲律宾获得临床批件 rhegen.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A Lyophilized COVID-19 mRNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366296 ↗ |
| Modality | Messenger RNA (mRNA) | “Lyophilized COVID-19 mRNA Vaccine” NCT05366296 ↗ |
| Route | Intramuscular | “intramuscular injection” NCT05366296 ↗ |